[Particular features of application of proton pump inhibitors (Rabeprazole) in children with the gastroesophageal reflux disease].
Khavkin
A I
AI
Zhikhareva
N S
NS
Rachkova
N S
NS
Babaian
M L
ML
Volynets
G V
GV
Khanakaeva
Z K
ZK
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000293:Adolescent; D001562:Benzimidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D005744:Gastric Acid / Q000378:metabolism / Q000502:physiology; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*; D006180:Proton-Translocating ATPases / Q000037:antagonists & inhibitors*; D064750:Rabeprazole; D013270:Stomach / Q000187:drug effects / Q000502:physiology
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001562:Benzimidazoles; D004791:Enzyme Inhibitors; D064750:Rabeprazole; D006180:Proton-Translocating ATPases; D009853:Omeprazole